Kailera’s $400m Series A Round Funds Ambitious Obesity Plans
A new contender emerges in obesity with pipeline assets from Jiangsu Hengrui, including a Phase III dual agonist, and an experienced team already focused on commercial hurdles.
A new contender emerges in obesity with pipeline assets from Jiangsu Hengrui, including a Phase III dual agonist, and an experienced team already focused on commercial hurdles.